Arsenic trioxide enhances the cytotoxic effect of cisplatin in head and neck squamous cell carcinoma cell lines

Kotowski,Ulana; Heiduschka,Gregor; Brunner,Markus; Erovic,Boban  M.; Martinek,Helga; Thurnher,Dietmar

doi:10.3892/ol.2012.643

Arsenic trioxide enhances the cytotoxic effect of cisplatin in head and neck squamous cell carcinoma cell lines

Authors:
- Ulana Kotowski
- Gregor Heiduschka
- Markus Brunner
- Boban M. Erovic
- Helga Martinek
- Dietmar Thurnher
View Affiliations

Affiliations: Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, A-1090 Vienna, Austria
Published online on: March 14, 2012 https://doi.org/10.3892/ol.2012.643
Pages: 1326-1330

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Arsenic trioxide (ATO) has been approved for the treatment of relapsed acute promyelocytic leukaemia. The aim of this study was to determine whether ATO would lead to cell death in head and neck squamous cell carcinoma (HNSCC) cell lines and whether it was able to enhance the cytotoxicity of cisplatin, a standard chemotherapeutic agent. The four HNSCC cell lines SCC9, SCC25, CAL27 and FADU were treated with ATO or cisplatin alone or with ATO and cisplatin in combination. Cytotoxicity assays, immunohistochemistry, western blot analysis and flow cytometry were carried out. Possible interactions between the two drugs were calculated using the Chou-Talalay equation. Ther results demonstrated a synergistic cytotoxic effect of the combination of ATO and cisplatin at high doses. The two agents induced apoptosis in all four HNSCC cell lines. In conclusion, this study showed that ATO is a promising therapeutic drug with cytotoxic effects in HNSCC. We demonstrated a synergistic effect in the combined treatment with cisplatin at high doses.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Miller WH Jr, Schipper HM, Lee JS, Singer J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res. 62:3893–3903. 2002.PubMed/NCBI
3	Gensini GF, Conti AA and Lippi D: The contributions of Paul Ehrlich to infectious disease. J Infect. 54:221–224. 2007. View Article : Google Scholar : PubMed/NCBI
4	Docampo R and Moreno SN: Current chemotherapy of human African trypanosomiasis. Parasitol Res. 90(Supp 1): S10–S13. 2003.
5	Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 339:1341–1348. 1998. View Article : Google Scholar : PubMed/NCBI
6	Shen ZX, Chen GQ, Ni JH, et al: Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:3354–3360. 1997.PubMed/NCBI
7	Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 19:3852–3860. 2001.PubMed/NCBI
8	Jiang XH, Wong BC, Yuen ST, et al: Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer. 91:173–179. 2001. View Article : Google Scholar : PubMed/NCBI
9	Seol JG, Park WH, Kim ES, et al: Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun. 265:400–404. 1999. View Article : Google Scholar : PubMed/NCBI
10	Akao Y, Nakagawa Y and Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett. 455:59–62. 1999. View Article : Google Scholar : PubMed/NCBI
11	Shen ZY, Shen J, Li QS, Chen CY, Chen JY and Yi Z: Morphological and functional changes of mitochondria in apoptotic esophageal carcinoma cells induced by arsenic trioxide. World J Gastroenterol. 8:31–35. 2002.PubMed/NCBI
12	Uslu R, Sanli UA, Sezgin C, et al: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res. 6:4957–4964. 2000.PubMed/NCBI
13	Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM and Ellison R: Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol. 125:470–476. 2004. View Article : Google Scholar : PubMed/NCBI
14	Kim KB, Bedikian AY, Camacho LH, Papadopoulos NE and McCullough C: A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer. 104:1687–1692. 2005. View Article : Google Scholar : PubMed/NCBI
15	Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL and Yang CH: Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs. 25:77–84. 2007. View Article : Google Scholar : PubMed/NCBI
16	Schiller GJ, Slack J, Hainsworth JD, et al: Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 24:2456–2464. 2006. View Article : Google Scholar : PubMed/NCBI
17	Whisler LC, Wood NB, Caldarelli DD, et al: Regulators of proliferation and apoptosis in carcinoma of the larynx. Laryngoscope. 108:630–638. 1998. View Article : Google Scholar : PubMed/NCBI
18	Evens AM, Tallman MS and Gartenhaus RB: The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res. 28:891–900. 2004. View Article : Google Scholar : PubMed/NCBI
19	Soignet SL: Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist. 6(Suppl 2): 11–16. 2001. View Article : Google Scholar : PubMed/NCBI
20	Chen GQ, Shi XG, Tang W, et al: Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): I. As₂O₃ exerts dose-dependent dual effects on APL cells. Blood. 89:3345–3353. 1997.PubMed/NCBI
21	Shao W, Fanelli M, Ferrara FF, et al: Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst. 90:124–133. 1998. View Article : Google Scholar : PubMed/NCBI
22	Seol JG, Park WH, Kim ES, et al: Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol. 18:249–255. 2001.PubMed/NCBI
23	Wang W, Qin SK, Chen BA and Chen HY: Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma. World J Gastroenterol. 7:702–705. 2001.PubMed/NCBI
24	Li H, Zhu X, Zhang Y, Xiang J and Chen H: Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction. J Exp Clin Cancer Res. 28:1102009. View Article : Google Scholar : PubMed/NCBI
25	Zhang N, Wu ZM, McGowan E, et al: Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci. 100:2459–2464. 2009. View Article : Google Scholar : PubMed/NCBI
26	Chung WH, Sung BH, Kim SS, Rhim H and Kuh HJ: Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. Int J Oncol. 34:1669–1679. 2009.PubMed/NCBI